 AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor TKI that selectively targets mutant forms of the epidermal growth factor receptor EGFR while sparing wild-type WT EGFR. The purpose of the study is to evaluate the pharmacokinetic PK and safety profile of oral AC0010; to determine the maximum tolerated dose MTD andor recommended Phase 2 dose RP2D of oral AC0010; to assess the safety and efficacy of AC0010 in previously treated mutant EGFR in NSCLC patients with EGFR T790M mutation. 